Search
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalIn order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for
Products: Lucentis 10mg/ml Solution for Injection, ACCENTRIX 10MG/ML SOLUTION FOR INJECTIONTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedBy the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … It is used in the UK as a treatment for migraine under the name of Clotam.[L1292] In the US, it presents a Status class I by the FDA.
Products: TOLFEDINE 4% W/V SOLUTION FOR INJECTION FOR DOGS AND CATS, Tolfine Solution for Injection 4.0% W/VInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigational[A225953,A225958] On December 11, 2020, the European Commission (EC) granted authorization for marketing inclisiran as the first and only approved siRNA for the treatment of adults with primary hypercholesterolemia … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: LEQVIO SOLUTION FOR INJECTION IN PREFILLED SYRINGE 284 MG/1.5 ML, Sybrava 284mg/1.5ml Solution for Injection in Pre-filled SyringeCeftaroline fosamil
go.drugbank.com/drugs/DB06590ApprovedInvestigationalCeftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Zinforo 600mg Powder for Concentrate for Solution for Infusion, Zinforo Powder for Concentrate for Solution for Infusion 600mg/vialAcetazolamide
go.drugbank.com/drugs/DB00819ApprovedInvestigationalVet approvedOne of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizur...
Products: Acetazolamide 500mg Powder for Solution for Injection, DIAMOX Sodium 500mg Powder for Solution for InjectionAntihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalPEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529].
Products: ADYNOVATE 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, ADYNOVATE 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTIONPiperacillin
go.drugbank.com/drugs/DB00319ApprovedInvestigationalSemisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.
Mixtures: PIPTAZ-AFT POWDER FOR SOLUTION FOR INJECTION 4.5G/VIAL, SALATAZ POWDER FOR SOLUTION FOR INJECTION/INFUSION 4.5G/VIALCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigationalPralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma [L37674]. … Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.
Products: SOLUTION FOR INFUSION 20MG/ML, Folotyn 20mg/ml Solution for InfusionCabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigational[A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].
Products: JEVTANA 60mg CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION, JEVTANA (CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION)Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria
Products: Soliris Concentrate for Solution for Infusion 300mg/vial, Soliris 10mg/ml Concentrate for Solution for Infusion